Biotechnology company developing first-in-class active immunotherapies using a CD180-based platform to overcome immune tolerance and treat cancer and chronic infections
Biotechnology company developing first-in-class active immunotherapies using a CD180-based platform to overcome immune tolerance and treat cancer and chronic infections. Its Antigen-Specific Immune Accelerants (ASIA) are designed to produce potent, specific, and durable immune responses.